aTyr Pharma (LIFE) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
May 13, 2021 4:05 PM EDTData from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC.
Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of two-year project.
Ended the quarter with $50.6 million in cash, cash equivalents and investments.
Company to host conference call and webcast today, May 13, at 5:00 p.m. EDT / 2:00 p.m. PDT.
SAN DIEGO, May 13,... More
